PD-L1 CPS ≥1 is required for pembrolizumab in persistent/recurrent/metastatic cervical ca...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-PDL1-CPS-CERVICAL |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-05-07 | actionability review required |
| Enfermedades | DIS-CERVICAL |
| Fuentes | SRC-ESMO-CERVICAL-2024 SRC-KEYNOTE-826-COLOMBO-2021 SRC-NCCN-CERVICAL-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-PDL1-CPS |
|---|---|
| Enfermedad | DIS-CERVICAL |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | pembrolizumab + paclitaxel + cisplatin/carboplatin ± bevacizumab (CPS≥1 1L per SRC-NCCN-CERVICAL-2025, SRC-ESMO-CERVICAL-2024, SRC-KEYNOTE-826-COLOMBO-2021) |
| Resumen de las pruebas | PD-L1 CPS ≥1 is required for pembrolizumab in persistent/recurrent/metastatic cervical cancer (KEYNOTE-826): pembrolizumab + paclitaxel + cisplatin/carboplatin ± bevacizumab 1L (CPS≥1 mOS 28.6 mo vs 16.5 mo, HR 0.64). FDA-approved 2021. Testing by IHC 22C3 pharmDx. Threshold-gated indication selection performed by the algorithm layer (IND-CERVICAL-METASTATIC-1L-PEMBRO-CHEMO-BEV); this BMA entry surfaces ESCAT context only. |
Notas
Variant_qualifier null — CPS≥1 threshold gating enforced by indication layer. KEYNOTE-826 source stub ingested (SRC-KEYNOTE-826-COLOMBO-2021). ESCAT IA confirmed by FDA approval and NCCN Category 1.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.